The Emirates Drug Establishment (EDE) has officially approved Etcamah, a groundbreaking oral therapy by AstraZeneca, offering a vital new option for breast cancer patients in the UAE. Specifically designed for individuals with advanced or metastatic breast cancer who have developed an ESR1 gene mutation during hormone therapy, this treatment acts as a next-generation estrogen receptor degrader. By effectively blocking and degrading estrogen receptors, the medication helps slow the growth of cancer cells that have become resistant to traditional endocrine treatments.

The approval follows a rigorous scientific review, including data from the successful Phase III SERENA-6 trial, which demonstrated significant improvements in progression-free survival for patients. Dr. Fatima Al Kaabi, director-general of the EDE, emphasized that this milestone highlights the UAE's commitment to building a flexible, high-standard pharmaceutical ecosystem that stays at the forefront of global medical innovation. By integrating this advanced therapy into the national healthcare system, the UAE continues to prioritize patient outcomes and the accessibility of life-changing, science-backed medical solutions for those battling advanced cancers.